Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas

Ayed, Dorra Ben; Khabir, Abdelmajid; Abid, M.; Bayrouti, Mohamed Issam; Gargouri, Ali; Sellami‐Boudawara, Tahya; Mokdad-Gargouri, Raja

doi:10.1016/j.acthis.2014.07.008

Cited by 11 publications

(8 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All of the studies were retrospective. Of all of the studies, 24 were performed in China 24-47, 12 in Japan 48-59, 3 in Greece 60-62 , 2 in Italy 63, 64, 2 in Poland 65, 66, 1 in Korea 67, 1in Germany 68, 2 in Egypt 69, 70, 1 in Finland 71, 1 in Timisoara 72, 1 in Turkey 73, 1 in Sultanate of Oman 74, 1 in Tunisia 75 and 1 in Saudi Arabia 76. A total of 10 publications were written in Chinese and 43 articles were written in English.…”

Section: Resultsmentioning

confidence: 99%

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

Xiong¹,

Zeng²,

Jiang³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

Gastric cancer (GC) threatens human health worldwide and we performed this meta-analysis to evaluate the clinical value of Ki-67/MKI67 in patients with GC. The combined hazard ratio (HR), odds ratio (OR) and 95% confidence interval (95% CI) were calculated to assess the relationships of Ki-67/MKI67 expression with prognoses and clinicopathological characteristics. Genes co-expressed with MKI67 were collected for Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) network analyses. In total, 53 studies with 7078 patients were included in this study. The pooled HRs indicated that an elevated expression of Ki-67/MKI67 predicted an unfavorable overall survival (HR: 1.54, 95% CI: 1.33-1.78, P<0.0001) and disease-free survival (HR: 2.28, 95% CI: 1.43-3.64, P<0.0001) in GC patients. Additionally, in patients with advanced GC, a high Ki-67/MKI67 expression was also significantly connected with OS (HR: 1.37, 95% CI: 1.18-1.60, P<0.0001). The combined ORs showed that Ki-67/MKI67 expression was related to TNM stage (stage III/IV versus stage I/II: OR=1.93, 95% CI=1.34-2.78, P<0.0001), tumor differentiation (poor versus well/moderate: OR=1.94, 95% CI=1.32-2.85, P=0.001), lymph node metastasis (yes versus no: OR=1.67, 95% CI=1.23-2.25, P=0.001), distant metastasis (yes versus no: OR=1.67, 95% CI=1.24-2.26, P=0.001) and tumor invasion depth (T3/T4 versus Tis/T1/T2: OR=1.98, 95% CI=1.60-2.44, P<0.0001). The results of GO, KEGG pathway and PPI network analyses indicated that Ki-67/MKI67 may be involved in the development of GC via influencing P53 signaling pathway. Ki-67/MKI67 could be a potential indicator to predict the prognosis of patients with GC and identify high-risk cases. Detecting Ki-67/MKI67 expression in clinic may be helpful in optimizing individual treatment and further improving the survival expectancy of patients with GC.

show abstract

Section: Resultsmentioning

confidence: 99%

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

Xiong¹,

Zeng²,

Jiang³

et al. 2019

J. Cancer

View full text Add to dashboard Cite

show abstract

“…We next asked whether the expression levels of RIP140 and/or LCoR were correlated with the expression of other proteins previously quantified in the same cohorts of CRC and GC patients [ 28 ][ 29 ][ 30 ][ 31 ][ 32 ]. As shown in Table 3 , in CRC and GC, RIP140 correlated positively with E-cadherin (p=0.049 and p=0.013, respectively) and COX-2 (p=0.021 and p=0.004, respectively).…”

Section: Resultsmentioning

confidence: 99%

“…Primary antibody binding was visualized with biotin- labeled secondary antibodies (Novolink Polymer, Leica Biosystems) and a streptavidin– peroxidase complex using diaminobenzidine as a chromogenic substrate (RE7280-K, Leica Biosystems). Stainings with the other antibodies directed against APC ( adenomatous polyposis coli ), β-catenin, p53, COX-2 and E-cadherin were described elsewhere for the same CRC [ 28 ] [ 29 ] and GC biopsies [ 30 ] [ 31 ] [ 32 ].…”

Section: Methodsmentioning

confidence: 99%

RIP140 and LCoR expression in gastrointestinal cancers

et al. 2017

Self Cite

View full text Add to dashboard Cite

The transcription coregulators RIP140 and LCoR are part of a same complex which controls the activity of various transcription factors and cancer cell proliferation. In this study, we have investigated the expression of these two genes in human colorectal and gastric cancers by immunohistochemistry. In both types of tumors, the levels of RIP140 and LCoR appeared highly correlated. Their expression tended to decrease in colorectal cancer as compared to adjacent normal tissues but was found higher in gastric cancer as compared to normal stomach. RIP140 and LCoR expression correlated with TNM and tumor differentiation. Significant correlations were observed with expression levels of key proteins involved in tumor progression and invasion namely E-cadherin and Cyclooxygenase-2. Survival analysis showed that patients with LCoRlow/RIP140high colorectal tumors have a significant prolonged overall and disease-free survival. In gastric cancer, high LCoR expression was identified as an independent marker of poor prognosis suggesting a key role in this malignancy. Altogether, these results demonstrate that RIP140 and LCoR have a prognostic relevance in gastrointestinal cancers and could represent new potential biomarkers in these tumors.

show abstract

“…It has been reported that Ki-67 is a nuclear protein with nuclear function, which is expressed in all phases of the cell cycle except G 0 phase. Therefore, Ki-67 has become the major markers of tumor proliferation (Ayed et al., 2014 ; Yamazaki et al., 2015 ). In this study, Ki-67 immunohistochemistry (Ki-67 IHC) was used to evaluate the proliferation level of different drug treated groups.…”

Section: Resultsmentioning

confidence: 99%

Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine–docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo

et al. 2018

View full text Add to dashboard Cite

Mitochondrial-targeting therapy was considered to be a promising approach for the efficient treatment of cancer while positive charge induced nonspecific cytotoxicity severely limits its application. To overcome this drawback, a novel mitochondria targeted conjugate triphenylphosphine-docetaxel (TD) has been synthesized successfully and incorporated it into liposomes (EPSLP/TD), which possessed excellent pH-sensitive characteristic, EphA 10 mediated active targetability as well as mitochondria-targeting capability. EPSLP/TD was characterized to have a small particle size, high-encapsulation efficiency and excellent pH-sensitive characteristic. Compared with DTX-loaded liposomes (EPSLP/DTX), EPSLP/TD possessed higher cytotoxicity against MCF-7 cell line. Mitochondrial-targeting assay demonstrated mitochondria-targeting moiety triphenylphosphine (TPP) could efficiently deliver DTX to mitochondria. Western immunoblotting assay indicated that EPSLP/TD could efficiently deliver antitumor drug to mitochondria and induce cell apoptosis via mitochondria-mediated apoptosis pathway. In vivo antitumor study demonstrated EPSLP/TD owed excellent in vivo antitumor activity. Histological assay demonstrated EPSLP/TD showed strongly apoptosis inducing effect, anti-proliferation effect and anti-angiogenesis effect. This work investigated the potential of hierarchical targeting pH-sensitive liposomes is a suitable carrier to activate mitochondria-mediated apoptosis pathway for cancer therapy.

show abstract

Clinicopathological and prognostic significance of p53, Ki-67, and Bcl-2 expression in Tunisian gastric adenocarcinomas

Cited by 11 publications

References 35 publications

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

Ki-67/MKI67 as a Predictive Biomarker for Clinical Outcome in Gastric Cancer Patients: an Updated Meta-analysis and Systematic Review involving 53 Studies and 7078 Patients

RIP140 and LCoR expression in gastrointestinal cancers

Eph A10-modified pH-sensitive liposomes loaded with novel triphenylphosphine–docetaxel conjugate possess hierarchical targetability and sufficient antitumor effect both in vitro and in vivo

Contact Info

Product

Resources

About